Kestra Medical Technologies (KMTS) insider plans $196K Rule 144 stock sale

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. insider Alfred J Ford has filed to sell common stock under Rule 144. The planned sale covers 8,681 shares of common stock through Merrill Lynch, with an aggregate market value of $196,284.58, and is expected on July 31, 2026 on NASDAQ.

The shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. Over the past three months, Ford has already sold 5,936 shares for an aggregate sale price of $135,120.73.

Key Figures

Planned shares to be sold: 8,681 shares Planned aggregate market value: $196,284.58 Planned sale date: 07/31/2026 +3 more

6 metrics

Planned shares to be sold 8,681 shares Common stock to be sold under Rule 144

Planned aggregate market value $196,284.58 Value of 8,681 shares to be sold

Planned sale date 07/31/2026 Expected date of Rule 144 sale on NASDAQ

Award vesting date 07/17/2026 Vesting date of performance share unit awards

Shares sold in past 3 months 5,936 shares Common stock sold by Alfred J Ford

Aggregate sale price (past 3 months) $135,120.73 Proceeds from 5,936 shares sold

Key Terms

Rule 144, performance share unit awards, equity compensation plan

3 terms

Rule 144 regulatory

"insider Alfred J Ford has filed to sell common stock under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

performance share unit awards financial

"relate to performance share unit awards that vested on July 17, 2026"

equity compensation plan financial

"granted under the issuer’s equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:33 PM Accepted by SEC EDGAR 07/31/2026 - 04:33 PM Learn about SEC filing dates

FAQ

What insider stock sale is disclosed for KMTS in this Form 144 filing?

Alfred J Ford plans to sell 8,681 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. common stock. The shares are to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $196,284.58 as disclosed in the filing.

When is the planned Rule 144 stock sale for KMTS expected to occur?

The planned Rule 144 sale of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) shares is expected on July 31, 2026. The filing indicates the common stock will be sold on NASDAQ through Merrill Lynch, subject to market conditions and Rule 144 requirements.

How many KMTS shares has Alfred J Ford sold in the last three months?

Over the past three months, Alfred J Ford has sold 5,936 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. common stock. These sales generated an aggregate sale price of $135,120.73, as itemized in the recent disclosure of prior transactions.

What is the origin of the KMTS shares being sold under Rule 144?

The KMTS shares being sold under Rule 144 originated from performance share unit awards. These awards vested on July 17, 2026 and were granted as part of KESTRA MEDICAL TECHNOLOGIES, LTD.’s equity compensation plan for the reporting person.

Which broker is handling the planned KMTS Rule 144 stock sale?

The planned KMTS Rule 144 stock sale will be handled by Merrill Lynch at its 225 Liberty Street, Floor 37, New York, NY address. The filing specifies Merrill Lynch as the broker for selling 8,681 shares of common stock on NASDAQ.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	8681	196284.58	58602497	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			8681	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Alfred J Ford 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	5936	135120.73

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)